Please login to the form below

Not currently logged in
Email:
Password:

Edelman wins AZ oncology porfolio

Edelman has won AstraZeneca's entire oncology portfolio, including Casodex and Zoladex.

The PR agency won the business against short-listed agency Cohn & Wolfe. Industry sources suggest the account could be worth up to £500,000. Edelman has previously worked on rival pharma firm Pfizer's oncology business.

The win follows AstraZeneca's decision to consolidate its oncology portfolio within one agency. The company had been using Axon Communications, Porter Novelli, Virgo Health PR and Cohn & Wolfe for individual cancer products. The latest additions to its cancer product range are Faslodex and Iressa.

AstraZeneca's head of communications, global marketing, Louise Fairburn said: "We have a number of PR directors working on the portfolio, and over time we have had a number of PR agencies, which didn't make sense."

She added: "We have a strong brand focus but not for the portfolio as a whole. This is an attempt to build a really strong global alliance in communications."

Edelman European health practice chair, Carolyn Paul, will head up the account. Fairburn will be the main point of contact for the agency.

Virgo will continue to handle the global support for Faslodex and Arimidex until quarter two next year when the accounts will be transferred to Edelman.

9th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics